Biotech firm Gilead Sciences rose sharply Friday, having touched a new high above 99, after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.’s cost-benefit authority. The stock added 3.13 to 99.49 in heavy volume, ending the week up 8%. Gilead Sciences (GILD) is a member of the IBD Sector Leaders as of Friday’s paper.